132 related articles for article (PubMed ID: 1758825)
1. Guidelines for the use of MS Contin tablets in the management of cancer pain.
Warfield CA
Postgrad Med J; 1991; 67 Suppl 2():S9-12; discussion S13. PubMed ID: 1758825
[TBL] [Abstract][Full Text] [Related]
2. Experience with a controlled-release oral morphine for cancer pain management.
Kim BS; Chung HC
Postgrad Med J; 1991; 67 Suppl 2():S82-6. PubMed ID: 1758823
[TBL] [Abstract][Full Text] [Related]
3. Morphine at gramme doses: kinetics, dynamics and clinical need.
Smith KJ; Miller AJ; McKellar J; Court M
Postgrad Med J; 1991; 67 Suppl 2():S55-9. PubMed ID: 1758817
[TBL] [Abstract][Full Text] [Related]
4. A clinical survey of controlled-release morphine sulphate for cancer pain relief in a Japanese hospice.
Tsuneto S; Hayashi A; Miyazaki M; Kashiwagi T
Postgrad Med J; 1991; 67 Suppl 2():S79-81. PubMed ID: 1758822
[TBL] [Abstract][Full Text] [Related]
5. Relationship between plasma concentration of morphine and analgesic effectiveness.
Yokokawa N; Hiraga K; Oguma T; Konishi M
Postgrad Med J; 1991; 67 Suppl 2():S50-4. PubMed ID: 1758816
[TBL] [Abstract][Full Text] [Related]
6. Oral opioids in the treatment of cancer pain.
Zylicz Z; Twycross RG
Neth J Med; 1991 Aug; 39(1-2):108-14. PubMed ID: 1660107
[TBL] [Abstract][Full Text] [Related]
7. Control of severe pain with sustained-release morphine tablets v. oral morphine solution.
Arkinstall WW; Goughnour BR; White JA; Stewart JH
CMAJ; 1989 Mar; 140(6):653-7, 661. PubMed ID: 2645988
[TBL] [Abstract][Full Text] [Related]
8. [Effects of sustained release morphine hydrochloride tablets in management of cancer pain: a survey of 567 patients].
Yu SY; Qiu H; Ma ZS; Chen J; Zhang Y; Chen LZ; Wang DL; Ma ZY
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):450-5. PubMed ID: 15061959
[TBL] [Abstract][Full Text] [Related]
9. [Roles of outpatient nurses in the care of cancer patients receiving MS Contin tablets].
Naito A; Sekiya Y
Gan To Kagaku Ryoho; 1999 Dec; 26 Suppl 2():354-7. PubMed ID: 10630247
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of pain in cancer with systemically administered opioids].
Enting RH; van der Rijt CC; Wilms EB; Lieverse PJ; de Wit R; Smitt PA
Ned Tijdschr Geneeskd; 2001 May; 145(20):950-4. PubMed ID: 11396259
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for use of controlled-release oral morphine in cancer pain management. Correlation with clinical experience.
Lapin J; Portenoy RK; Coyle N; Houde RW; Foley KM
Cancer Nurs; 1989 Aug; 12(4):202-8. PubMed ID: 2766263
[TBL] [Abstract][Full Text] [Related]
12. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
Binhas M; Krakowski I; Marty J
Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
[TBL] [Abstract][Full Text] [Related]
13. [Long-term therapy of tumor pain using morphine-retard tablets].
Sorge J; Lehmkuhl C; Lohse K; Herrmann H; Pichlmayr I
Med Klin (Munich); 1990 Sep; 85(9):523-8. PubMed ID: 2233610
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.
Hagen NA; Thirlwell M; Eisenhoffer J; Quigley P; Harsanyi Z; Darke A
J Pain Symptom Manage; 2005 Jan; 29(1):80-90. PubMed ID: 15652441
[TBL] [Abstract][Full Text] [Related]
15. The use of sustained-release morphine in a hospice setting.
Sherman LM
Pharmatherapeutica; 1987; 5(2):99-102. PubMed ID: 3659062
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
17. Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients.
Portenoy RK; Maldonado M; Fitzmartin R; Kaiko RF; Kanner R
Cancer; 1989 Jun; 63(11 Suppl):2284-8. PubMed ID: 2720577
[TBL] [Abstract][Full Text] [Related]
18. Principles of cancer pain management. Use of long-acting oral morphine.
Brooks I; De Jager R; Blumenreich M; George E; Savarese JJ
J Fam Pract; 1989 Mar; 28(3):275-80. PubMed ID: 2647896
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
